메뉴 건너뛰기




Volumn 31, Issue 4, 2013, Pages 436-441

A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; SATRAPLATIN;

EID: 84876720791     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.02.007     Document Type: Article
Times cited : (9)

References (21)
  • 1
    • 0034040527 scopus 로고    scopus 로고
    • An update on satraplatin: The first orally available platinum anticancer drug
    • Kelland L.R. An update on satraplatin: The first orally available platinum anticancer drug. Expert Opin Investig Drugs 2000, 9:1373-1382.
    • (2000) Expert Opin Investig Drugs , vol.9 , pp. 1373-1382
    • Kelland, L.R.1
  • 2
    • 0029121585 scopus 로고
    • DNA-binding properties of novel cis- and trans- platinum-based anticancer agents in 2 human ovarian carcinoma cell lines
    • Mellish K.J., Barnard C.F., Murrer B.A., et al. DNA-binding properties of novel cis- and trans- platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer 1995, 62:717-723.
    • (1995) Int J Cancer , vol.62 , pp. 717-723
    • Mellish, K.J.1    Barnard, C.F.2    Murrer, B.A.3
  • 3
    • 0036608548 scopus 로고    scopus 로고
    • JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumor cell lines with different sensitivities to cisplatin
    • Fokkema E., Groen H.J., Helder M.N., et al. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumor cell lines with different sensitivities to cisplatin. Biochem Pharmacol 2002, 63:1989-1996.
    • (2002) Biochem Pharmacol , vol.63 , pp. 1989-1996
    • Fokkema, E.1    Groen, H.J.2    Helder, M.N.3
  • 4
    • 0027253182 scopus 로고
    • Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): An orally active platinum drug
    • Kelland L.R., Abel G., McKeage M.J., et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): An orally active platinum drug. Cancer Res 1993, 53:2581-2586.
    • (1993) Cancer Res , vol.53 , pp. 2581-2586
    • Kelland, L.R.1    Abel, G.2    McKeage, M.J.3
  • 5
    • 0026665349 scopus 로고
    • Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin
    • Twentyman P.R., Wright K.A., Mistry P., et al. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 1992, 52:5674-5680.
    • (1992) Cancer Res , vol.52 , pp. 5674-5680
    • Twentyman, P.R.1    Wright, K.A.2    Mistry, P.3
  • 6
    • 0029089517 scopus 로고
    • A phase I and pharmacology study of an oral platinum complex, JM216: Dose-dependent pharmacokinetics with single-dose administration
    • McKeage M.J., Mistry P., Ward J., et al. A phase I and pharmacology study of an oral platinum complex, JM216: Dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995, 36:451-458.
    • (1995) Cancer Chemother Pharmacol , vol.36 , pp. 451-458
    • McKeage, M.J.1    Mistry, P.2    Ward, J.3
  • 7
    • 0030742993 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer
    • McKeage M.J., Raynaud F., Ward J., et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997, 15:2691-2700.
    • (1997) J Clin Oncol , vol.15 , pp. 2691-2700
    • McKeage, M.J.1    Raynaud, F.2    Ward, J.3
  • 9
    • 0032423757 scopus 로고    scopus 로고
    • Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days
    • Sessa C., Minoia C., Ronchi A., et al. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol 1998, 9:1315-1322.
    • (1998) Ann Oncol , vol.9 , pp. 1315-1322
    • Sessa, C.1    Minoia, C.2    Ronchi, A.3
  • 10
    • 34447536763 scopus 로고    scopus 로고
    • Preclinical antitumor activity of the oral platinum analog satraplatin
    • Wosikowski K., Lamphere L., Unteregger G., et al. Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 2007, 60:589-600.
    • (2007) Cancer Chemother Pharmacol , vol.60 , pp. 589-600
    • Wosikowski, K.1    Lamphere, L.2    Unteregger, G.3
  • 11
    • 0031159653 scopus 로고    scopus 로고
    • Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation
    • Judson I., Cerny T., Epelbaum R., et al. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation. Ann Oncol 1997, 8:604-606.
    • (1997) Ann Oncol , vol.8 , pp. 604-606
    • Judson, I.1    Cerny, T.2    Epelbaum, R.3
  • 12
    • 0032791924 scopus 로고    scopus 로고
    • Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer
    • Fokkema E., Groen H.J., Bauer J., et al. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 1999, 17:3822-3827.
    • (1999) J Clin Oncol , vol.17 , pp. 3822-3827
    • Fokkema, E.1    Groen, H.J.2    Bauer, J.3
  • 13
    • 0036169155 scopus 로고    scopus 로고
    • A phase II trial of JM-216 in cervical cancer: An NCIC CTG study
    • Trudeau M., Stuart G., Hirte H., et al. A phase II trial of JM-216 in cervical cancer: An NCIC CTG study. Gynecol Oncol 2002, 84:327-331.
    • (2002) Gynecol Oncol , vol.84 , pp. 327-331
    • Trudeau, M.1    Stuart, G.2    Hirte, H.3
  • 14
    • 8644219658 scopus 로고    scopus 로고
    • Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily × 5 in hormone refractory prostate cancer (HRPC)
    • Latif T., Wood L., Connell C., et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily × 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs 2005, 23:79-84.
    • (2005) Invest New Drugs , vol.23 , pp. 79-84
    • Latif, T.1    Wood, L.2    Connell, C.3
  • 15
    • 20944439837 scopus 로고    scopus 로고
    • Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer
    • Sternberg C.N., Whelan P., Hetherington J., et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005, 68:2-9.
    • (2005) Oncology , vol.68 , pp. 2-9
    • Sternberg, C.N.1    Whelan, P.2    Hetherington, J.3
  • 16
    • 4744366279 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    • Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
    • (2004) N Engl J Med , vol.351 , pp. 1502-1512
    • Tannock, I.F.1    de Wit, R.2    Berry, W.R.3
  • 17
    • 4744337716 scopus 로고    scopus 로고
    • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    • Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
    • (2004) N Engl J Med , vol.351 , pp. 1513-1520
    • Petrylak, D.P.1    Tangen, C.M.2    Hussain, M.H.3
  • 18
    • 41549116526 scopus 로고    scopus 로고
    • Satraplatin, an oral platinum analog, is active and synergistic with paclitaxel and docetaxel in prostate carcinoma models
    • Lamphere L., Obermayr F., Caligiuri M., et al. Satraplatin, an oral platinum analog, is active and synergistic with paclitaxel and docetaxel in prostate carcinoma models. J Clin Oncol [Meeting Abstract] 2006, 24:14620.
    • (2006) J Clin Oncol [Meeting Abstract] , vol.24 , pp. 14620
    • Lamphere, L.1    Obermayr, F.2    Caligiuri, M.3
  • 19
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 20
    • 71849107626 scopus 로고    scopus 로고
    • Phase II trial of satraplatin (S) and paclitaxel (P) in first-line advanced non-small-cell lung cancer (NSCLC) treatment: Final results
    • Thompson D.S., Spigel D.R., Hainsworth J.D., et al. Phase II trial of satraplatin (S) and paclitaxel (P) in first-line advanced non-small-cell lung cancer (NSCLC) treatment: Final results. J Clin Oncol [Meeting Abstracts] 2008, 26:19023.
    • (2008) J Clin Oncol [Meeting Abstracts] , vol.26 , pp. 19023
    • Thompson, D.S.1    Spigel, D.R.2    Hainsworth, J.D.3
  • 21
    • 73949098659 scopus 로고    scopus 로고
    • Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial
    • Sternberg C.N., Petrylak D.P., Sartor O., et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. J Clin Oncol 2009, 27:5431-5438.
    • (2009) J Clin Oncol , vol.27 , pp. 5431-5438
    • Sternberg, C.N.1    Petrylak, D.P.2    Sartor, O.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.